entertainment -WSS

entertainment

author：focus 2025-09-05 09:18:06 - browse：416

A purple number 3 with an eye is surrounded by smaller, black number 3s on a green background — 3 to watch coverage from STAT — Christine Kao/STAT

Every winter, like Punxsutawney nobles, biotech’s many thought leaders gather for the J.P. Morgan Healthcare Conference to pick apart the year that was and prognosticate about the one to come. The consensus, in good markets and bad, is almost always cautious optimism for boom times ahead, a prediction that in recent years has had groundhog-level accuracy.

But after two years of steady decline, 2024 might finally prove them right. Biotech is on the upswing, driven by the rise of some headline-grabbing medicines, the advance of cutting-edge technologies, and a few reminders that big drug companies are still willing to pay billions of dollars for small ones.

Here are three major themes that we expect to drive the news in 2024 and determine whether biotech’s comeback is a sustainable trend or an interest-rate phenomenon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： A single Democrat is willing to weaken Medicare negotiation power

entertainment

WSS

Hospitals are piloting generative AI tools as regulators play catch

Flagship Pioneering startup Sonata Therapeutics lays off 21

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

A new drug could help frostbite victims avoid its ravages

Johnson & Johnson sued for allegedly overpaying for workers' drugs

MD Anderson's Padmanee Sharma responds to research credit suit

hotspot

entertainment

focus

23andMe had bad news about my health. I wish a person had delivered it

Abridge raises $150m as clinical notes automation market heats up

How to save PrEP access — and even expand it

Top private equity targets in 2023: cardiology, clinical trials, lasers

Anesthesiologist group: stop taking Ozempic before surgery

Ukraine seeks to reclaim its role as a hub for clinical trials

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

WATCH: Why do our ears pop?

Alkermes shareholders re

Surgery pushed Ben Carson to fame

Wikipedia

AstraZeneca stays mum on Medicare drug pricing negotiations

Elevance, SCAN deals highlight health insurer acquisition scrutiny

A new drug could help frostbite victims avoid its ravages

The Biogen Aduhelm mess could happen again

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Readout Newsletter: Amgen, Regeneron, BGI Group and more

knowledge

leisure time

entertainment

entertainment